Category Archives: Institutional and special event

Premiers résultats des enquêtes de santé publique de l’Inserm sur la Covid-19 : facteurs de risque individuels et sociaux

Pour répondre aux questions de santé publique posées par l’épidémie de Covid-19, des enquêtes multidisciplinaires de grande ampleur ont été lancées à l’Inserm. Deux grandes enquêtes de santé publique : SAPRIS et EpiCoV, livrent aujourd’hui leurs premiers résultats.

Also posted in Press releases, Public health | Tagged | Comments closed

Fibromyalgia, Knowledge Overview and Recommendations: An Inserm Collective Expert Review

Inserm was tasked by France’s Health Directorate with conducting a Collective Expert Review in order to take stock of the scientific knowledge on fibromyalgia in adults, and also to explore the potential existence of a similar syndrome in children and adolescents. The objective was also to recommend measures and establish research priorities in order to better understand fibromyalgia and improve patient care.

Also posted in Press releases, Public health | Tagged | Comments closed

COVID-19 Vaccines: 25,000 Volunteers Needed for Large-Scale Clinical Trials in France – Registration Now Open

Today, COVIREIVAC opens the registration process for volunteers to participate in the first large-scale clinical trials in France.

Also posted in Press releases, Immunology, inflammation, infectiology and microbiology, Public health | Tagged | Comments closed

Inserm Launches a Platform Evaluating COVID-19 Vaccine Candidates for the Conduct of Large-Scale Quality Trials

Inserm, with the support of the REACTing network, Public Health France, the country’s university hospitals, and the French College of Teachers in General Practice, is launching COVIREIVAC. This platform for the clinical evaluation of COVID-19 vaccine candidates will make it possible to test them rigorously and obtain robust data on their safety and ability to induce an immune response (immunogenicity).

Also posted in Press releases, Public health | Tagged | Comments closed

Discovery: Stopping inclusions in two treatment groups

Les deux bras testant la combinaison lopinavir/ritonavir avec ou sans interféron bêta sont arrêtés dans les essais cliniques Solidarity et Discovery. Compte tenu de la nature adaptative des deux essais, une réflexion est en cours sur l’évolution du protocole. Des publications dans des journaux internationaux à comité de lecture sont en préparation concernant tant l’évaluation de l’hydroxychloroquine que du lopinavir/ritonavir.

Also posted in Press releases | Tagged | Comments closed

COVID-19 and the Environment: A European Program Coordinated by Inserm gives its recommendations

Launched in 2019, the primary objective of the Health Environment Research Agenda for Europe (HERA) is to provide the European Commission with an environment, climate, and health research agenda for 2020-2030.

Also posted in Press releases, Public health | Tagged | Comments closed

L’hydroxychloroquine pourra être réintroduite dans Discovery après le feu vert des autorités compétentes

L’hydroxychloroquine pourra être réintroduite dans Discovery après le feu vert des autorités compétentes

Also posted in Press releases | Tagged | Comments closed

Inclusions in the hydroxychloroquine group of the Discovery trial are suspended.

Les inclusions dans le groupe hydroxychloroquine de l’essai Discovery sont suspendues depuis dimanche 24 mai.

Also posted in Press releases | Tagged | Comments closed

Milestone: Inserm’s commitment to the fight against the Covid-19 pandemic

First identified in the central Chinese city of Wuhan in December 2019, the novel SARS-CoV-2 coronavirus has rapidly spread across the world, leading to the most serious pandemic in recent history.

Also posted in Press releases, Public health | Tagged | Comments closed

Point d’étape sur l’essai Discovery promu par l’Inserm

L’essai Discovery évalue l’efficacité de différents traitements antiviraux visant à limiter la multiplication du virus observée chez certains patients hospitalisés dont l’état s’aggrave souvent autour du septième jour de maladie.

Also posted in Press releases | Tagged | Comments closed
fermer
fermer
RSS Youtube